학술논문
A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3 /5-HT7 inhibitor
Document Type
Article
Author
Source
In: Psychopharmacology . (Psychopharmacology, September 2022, 239(9):3009-3018)
Subject
Language
English
ISSN
14322072
00333158
00333158